A Phase 4 interventional study of Encepur Adults in Virus Diseases, sponsored by GlaxoSmithKline. Completed at 1 site in Czechia. Open to participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Virus Diseases by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Virus Diseases · GlaxoSmithKline.
Among the 20 studies in Virus Diseases by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 5 in phase 4, and was the 14th registered.
656 studies on the registry are indexed under Virus Diseases; 84 are open to participants now.
Browse Virus Diseases studies →None of the 20 studies in Virus Diseases by GlaxoSmithKline is open now. The open studies under Virus Diseases, anywhere →
Of the 64 Virus Diseases studies recruiting now, 30 (47%) set no upper age limit and 22 (34%) stop at 75 or younger; 28 take children under 18; 27 take healthy volunteers.
This study: 25 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2017.
This study's enrollment of 194 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 177 across the 20 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Virus Diseases by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine. This study will further investigate the booster response in subjects who will receive their second booster dose* in this study.
* Any booster given in this study will be the second that the subject has received (with regard to the follow-up of the previous study).
Inclusion Criteria:
Inclusion criteria for all subjects:
Additional inclusion criteria for subjects who will need a second booster dose:
Exclusion Criteria:
Each subject must not be:
Each subject must not have:
Each subject who will receive the second booster vaccination in this study additionally to the exclusion criteria above must not have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received primary vaccination in study V48P7 on Days 0, 28 (+10) and 300 (+21) (55 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (55 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their Neutralization Test (NT) titer resulted below 10.
Biological: Encepur Adults
Participants who received primary vaccination in study V48P7 on Days 0, 7 (+3) and 21 (+7) (66 participants) and who received a booster vaccination either in study V48P7E1 (NCT00387634) (9 participants) or before enrolment in study V48P7E1 (NCT00387634) (40 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
Biological: Encepur Adults
Participants who received primary vaccination in study V48P7 on Days 0, 14 (+3) and 300 (+21) (133 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (109 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
Biological: Encepur Adults
One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 11
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
Time frame: At Year 11
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 12
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
Time frame: At Year 12
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 13
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
Time frame: At Year 13
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 14
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
Time frame: At Year 14
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 15
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
Time frame: At Year 15
Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 11
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 11. GMTs were assessed for following age subgroups: 25 to 49 years, equal to or above (\>=) 50 years and \>= 60 years.
Time frame: At Year 11
Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 12
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 12. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
Time frame: At Year 12
Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 13
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 13. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
Time frame: At Year 13
Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 14
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 14. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
Time frame: At Year 14
Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 15
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 15. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
Time frame: At Year 15
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 2 and Equal to or Above 10 as Measured by GSK Biologicals' NT, Overall and by Study Group
Immunogenicity was planned to be measured in terms of percentage of participants with TBE Neutralizing Antibody Titers \>= 2 and \>= 10 at 21 days after the booster vaccination.
Time frame: At 21 days after the booster vaccination
Geometric Mean Antibody Titers (GMTs) as Measured by GSK Biologicals' NT, Overall and by Study Group
Immunogenicity was planned to be measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination.
Time frame: At 21 days after the booster vaccination
Geometric Mean Ratios (GMRs) Blood Draw After/Before Booster as Measured by GSK Biologicals' NT, Overall and by Study Group
Immunogenicity was planned to be measured in terms of GMRs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination.
Time frame: At 21 days after the booster vaccination
Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to and Above 10 as Measured by GSK Biologicals' NT, Overall and by Study Group
Immunogenicity was measured in terms of percentage of participants with TBE Neutralizing Antibody Titers \>= 10 from Year 1 to Year 15.
Time frame: From Year 1 up to Year 15
Number of Participants With Serious Adverse Events (SAEs)
SAEs are defined as any untoward medical occurrence that results in death, is life- threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 to Day 21 after booster vaccination
194 subjects, who participated in study V48P7E2(NCT01562444), received in a parent V48P7 study one of the following primary schedules: rapid(R), conventional(C), or accelerated conventional(AC), who received a booster dose in study V48P7E1(NCT00387634) or before study V48P7E1(only R-schedule), and agreed to participate in this study, were enrolled.
| Milestone | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Started | 50 | 43 | 101 |
| Completed | 46 | 43 | 99 |
| Not completed | 4 | 0 | 2 |
| Withdrew: Serious adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Other | 2 | 0 | 0 |
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 11 | 100 (92.6 to 100) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 12 | 98.0 (89.4 to 99.9) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 13 | 95.9 (86.0 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 14 | 95.9 (86.0 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers \>= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 15 | 95.8 (85.7 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 11. GMTs were assessed for following age subgroups: 25 to 49 years, equal to or above (\>=) 50 years and \>= 60 years.
| Titers | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| 25 to 49 Years of Age | 368.8 (208.9 to 651.1) | 301.5 (168.7 to 538.7) | 235.2 (161.6 to 342.3) |
| >=50 Years of Age | 129.6 (76.7 to 218.8) | 177.4 (100.0 to 314.9) | 128.1 (87.7 to 187.0) |
| >=60 Years of Age | 127.5 (61.3 to 265.4) | 160.2 (79.2 to 324.0) | 103.0 (62.6 to 169.5) |
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 12. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
| Titers | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| 25 to 49 Years of Age | 323.7 (185.0 to 566.3) | 334.6 (184.6 to 606.4) | 264.3 (179.9 to 388.3) |
| >=50 Years of Age | 154.5 (87.6 to 272.4) | 205.8 (110.6 to 383.0) | 158.2 (105.0 to 238.3) |
| >=60 Years of Age | 133.6 (62.5 to 285.6) | 190.8 (92.0 to 395.9) | 141.0 (84.2 to 236.3) |
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 13. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
| Titers | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| 25 to 49 Years of Age | 196.9 (112.2 to 345.6) | 238.4 (131.1 to 433.6) | 172.8 (117.3 to 254.3) |
| >=50 Years of Age | 98.3 (56.6 to 170.9) | 132.1 (73.0 to 238.9) | 110.9 (75.0 to 164.0) |
| >=60 Years of Age | 93.5 (44.7 to 195.6) | 114.8 (56.5 to 233.4) | 96.9 (58.7 to 160.0) |
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 14. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
| Titers | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| 25 to 49 Years of Age | 299.7 (164.2 to 547.0) | 299.1 (157.8 to 567.1) | 248.2 (164.1 to 375.4) |
| >=50 Years of Age | 147.5 (81.2 to 268.0) | 169.7 (89.5 to 321.8) | 131.1 (86.0 to 200.0) |
| >=60 Years of Age | 139.4 (67.2 to 289.3) | 149.9 (74.3 to 302.4) | 117.9 (71.8 to 193.7) |
Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 15. GMTs were assessed for following age subgroups: 25 to 49 years, \>= 50 years and \>= 60 years.
| Titers | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| 25 to 49 Years of Age | 217.6 (125.2 to 378.2) | 281.6 (156.5 to 506.9) | 183.9 (125.7 to 268.9) |
| >=50 Years of Age | 98.9 (54.4 to 180.0) | 157.0 (83.8 to 294.1) | 103.3 (67.9 to 156.9) |
| >=60 Years of Age | 114.1 (52.5 to 247.8) | 158.1 (77.5 to 322.7) | 90.7 (54.2 to 151.7) |
Immunogenicity was planned to be measured in terms of percentage of participants with TBE Neutralizing Antibody Titers \>= 2 and \>= 10 at 21 days after the booster vaccination.
No measurements were reported for this outcome.
Immunogenicity was planned to be measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination.
No measurements were reported for this outcome.
Immunogenicity was planned to be measured in terms of GMRs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination.
No measurements were reported for this outcome.
Immunogenicity was measured in terms of percentage of participants with TBE Neutralizing Antibody Titers \>= 10 from Year 1 to Year 15.
| Percentage of participants | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Year 1 | 100 (92.5 to 100) | 100 (91.6 to 100) | 100 (96.4 to 100) |
| Year 2 | 100 (92.6 to 100) | 100 (91.6 to 100) | 100 (96.3 to 100) |
| Year 3 | 100 (92.6 to 100) | 100 (91.6 to 100) | 100 (96.4 to 100) |
| Year 4 | 100 (92.3 to 100) | 97.6 (87.1 to 99.9) | 100 (96.4 to 100) |
| Year 5 | 100 (92.6 to 100) | 100 (91.8 to 100) | 100 (96.4 to 100) |
| Year 6 | 100 (92.6 to 100) | 100 (91.8 to 100) | 100 (96.4 to 100) |
| Year 7 | 100 (92.6 to 100) | 100 (91.8 to 100) | 100 (96.3 to 100) |
| Year 8 | 100 (92.5 to 100) | 100 (91.6 to 100) | 100 (96.3 to 100) |
| Year 9 | 100 (92.1 to 100) | 100 (91.6 to 100) | 100 (96.3 to 100) |
| Year 10 | 100 (92.3 to 100) | 100 (91.6 to 100) | 100 (96.3 to 100) |
| Year 11 | 100 (92.3 to 100) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
| Year 12 | 97.9 (88.9 to 99.9) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
| Year 13 | 95.8 (85.7 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
| Year 14 | 95.8 (85.7 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
| Year 15 | 95.8 (85.7 to 99.5) | 100 (91.8 to 100) | 99.0 (94.6 to 100) |
SAEs are defined as any untoward medical occurrence that results in death, is life- threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | Conventional Group |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 |
Collected over Serious adverse events that led to withdrawal or were related to study vaccination were collected throughout the study period (Year 11 to Year 15). Other serious adverse events were collected only after the booster vaccination administration (Day 0-Day 21).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Conventional Group | 1/50 (2%) | 1/50 (2%) | — |
| Accelerated/Rapid Group | 0/43 (0%) | 0/43 (0%) | — |
| Accelerated Conventional Group | 1/101 (1%) | 1/101 (1%) | — |
| Event | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group |
|---|---|---|---|
| Death due to glioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 0/43 | 0/101 |
| Death due to primary COVID-19 pneumoniaInfections and infestations | 0/50 | 0/43 | 1/101 |
| Age, Customized(Years) | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group | Total |
|---|---|---|---|---|
| Mean | 47.0 ± 14.1 | 48.8 ± 15.3 | 48.1 ± 14.5 | 48.0 ± 14.5 |
| Sex: Female, Male(Participants) | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group | Total |
|---|---|---|---|---|
| Female | 31 | 22 | 52 | 105 |
| Male | 19 | 21 | 49 | 89 |
| Race/Ethnicity, Customized(Participants) | Conventional Group | Accelerated/Rapid Group | Accelerated Conventional Group | Total |
|---|---|---|---|---|
| WHITE | 50 | 43 | 101 | 194 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Oct 2021, 48 months.
Results were first posted in Mar 2024, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.